Navigation Links
OncoSec Closes $7.75 Million Public Offering
Date:3/28/2012

SAN DIEGO, March 28, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.  Additionally, investors received Warrants to purchase up to 31,000,000 shares of common stock at an exercise price of $0.35 per share for a term of five years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering were $7.75 million and net proceeds, after deducting the placement agent's fee and estimated offering expenses payable by OncoSec, were approximately $7.2 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction.  Roth Capital Partners, LLC served as financial advisors to the Company in the offering.

About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, without limitation, the satisfaction of the closing conditions and our dependence on the investors' commitments to fulfill their obligations in connection with our private placement financing, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoSec to Present at 10th Annual BioPartnering North America
2. OncoSec Medical Reports Third Quarter 2011 Financial Results
3. OncoSec Announces Clinical Leadership Appointments
4. OncoSec Announces Leadership Team Appointments
5. OncoSec Medical Featured in Medical Device Daily
6. OncoSec Medical Appoints Punit Dhillon as President and CEO
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
9. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
10. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
11. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Maryland (PRWEB) , ... May 22, 2017 , ... ... Olsen, joined with other leaders of the Maryland Biohealth community in developing and ... globally recognized Top 3 U.S. BioHealth Innovation Hub by 2023. ...
(Date:5/21/2017)... Diego, CA (PRWEB) , ... May 20, 2017 ... ... support tool that helps avoid the lengthy trial and error process by finding ... patients. It can also strengthen the doctor-patient relationship through a personalized approach ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of the ... Of Wales Private Hospital. The procedure was performed on a 46-year-old male patient ... treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl Peck, MD ... Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has ... and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP and ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
Breaking Biology News(10 mins):